Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. [electronic resource]
Producer: 20180223Description: 72311-72321 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Atherosclerosis -- blood
- Cross-Sectional Studies
- Cytokines -- blood
- Dyslipidemias -- blood
- Female
- Genetic Predisposition to Disease
- Humans
- Imatinib Mesylate -- therapeutic use
- Incidence
- Inflammation -- chemically induced
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Oxidation-Reduction -- drug effects
- Polymorphism, Single Nucleotide
- Prospective Studies
- Protein Kinase Inhibitors -- therapeutic use
- Pyrimidines -- therapeutic use
- Retrospective Studies
- Risk Factors
- Scavenger Receptors, Class E -- genetics
- Thrombosis -- blood
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.